Research Progress and Mechanism Study of IL-17A/IL-17F Dual Neutralizing Antibody
The IL-17 family of cytokines plays a central driving role in the pathological processes of various autoimmune diseases. Among them, IL-17A and IL-17F, as key members of this family, share overlapping pro-inflammatory functions.
- Recent Advances
- Product Information
I. IL-17 Pathway and Autoimmune Diseases
IL-17 family cytokines play a central driving role in the pathological processes of various autoimmune diseases. Among them, IL-17A and IL-17F, as key members of this family, exhibit overlapping pro-inflammatory functions and can synergize with other inflammatory mediators to jointly drive chronic inflammatory responses and multi-tissue damage. Based on this mechanism, the IL-17 signaling pathway has become a critical therapeutic target for diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. In related mechanism studies and drug development, the Human IL-17F Kit (HICA) has been widely used to detect IL-17F expression levels, providing an important quantitative tool for assessing the role of this cytokine in disease and the effects of drug interventions.
II. Clinical Progress of Dual Neutralizing Antibodies
(1) Submission of Marketing Applications
A dual neutralizing monoclonal antibody targeting both IL-17A and IL-17F has submitted marketing applications to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of moderate-to-severe plaque psoriasis. This antibody is a humanized IgG1 subtype that efficiently and selectively neutralizes both IL-17A and IL-17F cytokines.
(2) Preclinical Research Basis
Preclinical studies have shown that dual neutralization of IL-17A and IL-17F significantly reduces the expression levels of inflammation-related genes and cytokines compared to blocking IL-17A alone, while also exerting stronger inhibitory effects on the migration of disease-related immune cells. This finding provides a theoretical basis for the dual inhibition strategy.
(3) Phase III Clinical Trial Results
In Phase III clinical studies for moderate-to-severe chronic plaque psoriasis, the dual neutralizing antibody demonstrated excellent skin lesion clearance. Two key clinical studies evaluated the efficacy and safety of the drug in adult patients. The results showed that at week 16, compared to the placebo group, a significantly higher proportion of patients in the treatment group achieved at least 90% improvement in the Psoriasis Area and Severity Index (PASI 90) and complete or almost complete clearance of skin lesions (IGA 0/1). Compared to marketed IL-12/IL-23 inhibitors, the drug also showed superior efficacy. Additionally, most patients maintained this remission state for up to one year, suggesting durable therapeutic benefits from the dual neutralization strategy.
III. New Discoveries in IL-17 Pathway Mechanism Research
(1) Discovery of IL-17RC-Independent Signaling Pathway
Recent fundamental research on the IL-17 signaling pathway has deepened. A study published in Immunity revealed a new mechanism of IL-17F signal transduction: IL-17RC can function independently of IL-17RA, forming homodimers to bind IL-17F and activate downstream signaling pathways that do not depend on IL-17RA. This discovery expands the understanding of the functional diversity of the IL-17 family and provides new insights for therapeutic interventions in diseases such as inflammatory bowel disease (IBD). In this mechanistic study, the Human IL-17F Kit (HICA) was used to detect IL-17F expression and binding properties under different experimental conditions, providing key data to elucidate this new pathway.
(2) Association Between IL-17 and the Nervous System
The function of IL-17 is not limited to peripheral immune regulation. Clinical observations have shown that some children with autism spectrum disorder (ASD) exhibit temporary improvements in behavioral symptoms during fever-associated inflammation. Mechanistic studies indicate that IL-17 production during inflammation can promote social behavior in animal models of neurodevelopmental disorders. This finding suggests that the IL-17 signaling pathway may serve as a new therapeutic target for neurodevelopmental disorders. In related studies, the Human IL-17F Kit (HICA) was used to detect changes in IL-17F expression in animal models and cell samples, providing quantitative means to reveal the role of IL-17 in neuroimmune regulation.
IV. Applications of Detection Tools in IL-17F Research
As understanding of the biological functions of IL-17F and its role in diseases continues to deepen, the need for precise quantification of IL-17F expression levels has become increasingly prominent. The Human IL-17F Kit (HICA) is designed based on the principle of sandwich enzyme-linked immunosorbent assay (ELISA), featuring high sensitivity, specificity, and excellent reproducibility. It plays an important role in the following research areas:
(1) Fundamental Mechanism Research: Used to detect IL-17F expression levels in cell culture supernatants, tissue homogenates from animal models, and body fluids, exploring Th17 cell differentiation regulation and interactions between IL-17F and other cytokines.
(2) Disease Mechanism Exploration: By measuring IL-17F concentrations in patient serum, plasma, or local tissues, analyzing its association with disease activity, clinical manifestations, and prognosis, providing data support for IL-17F as a disease biomarker.
(3) Drug Development and Evaluation: Used in preclinical studies to assess the inhibitory effects of candidate drugs on IL-17F expression; serving as a pharmacodynamic indicator in clinical trials to monitor changes in IL-17F levels during treatment, providing basis for drug dosage selection and efficacy evaluation.
V. Which Manufacturers Provide the Human IL-17F Kit (HICA)?
Nanjing UA-Bio Technology Co., Ltd. (UA-Bio) has independently developed the "Human IL-17F Kit (HICA)", a high-performance in vitro detection platform specifically designed for studying mucosal immune inflammation and the key pathways of Th17 cell function. This kit aims to accurately and efficiently quantify the immunobinding activity of human interleukin-17F (IL-17F) protein, providing stable and reliable standardized solutions for your research in areas such as psoriasis, inflammatory bowel disease, asthma, and antibody drug development, including efficacy evaluation, mechanism studies, and biosimilar analysis.
| Core Advantages of the Product |
|---|
| High Purity and Complete Biological Activity: The core components of the kit utilize high-purity, high-biological-activity human IL-17F protein validated through multidimensional quality control. This protein maintains the correct native homodimer conformation and full receptor (IL-17RA/IL-17RC) binding capacity, accurately simulating the pro-inflammatory signals and tissue immune regulation mediated by IL-17F under physiological conditions, ensuring the accuracy, reproducibility, and functional relevance of binding experimental data. |
| Excellent Batch-to-Batch Consistency and Stability: Leveraging an internationally leading recombinant protein expression platform and highly standardized purification processes, combined with a rigorous quality control release system, the product exhibits outstanding long-term stability and excellent batch-to-batch consistency. This provides solid and reliable quality assurance for your long-term, continuous key experiments and high-throughput screening work. |
| Ready-to-Use Flexible Detection Platform: Based on optimized enzyme-linked immunosorbent assay (ELISA) principles, the kit provides pre-coated strips, highly specific detection antibodies, standards, and a complete set of optimized buffer systems. It is simple and fast to operate, with high sensitivity and specificity, suitable for various research applications such as anti-IL-17F antibody/receptor antagonist screening, neutralization activity determination, competitive binding experiments, affinity analysis, and immunogenicity evaluation. |
| Complete Solutions and Professional Support: We provide fully validated standard experimental protocols, typical dose-response curves, and detailed result interpretation guidelines to help you quickly establish stable and reproducible detection processes. The Nanjing UA-Bio professional technical team offers comprehensive technical consultation and support for your research design, experimental optimization, and data analysis. |
Nanjing UA-Bio Technology Co., Ltd. is committed to providing cutting-edge, high-quality core reagents and tools for immunology, cell therapy, and innovative drug development. For detailed technical parameters, validation data, or specific application inquiries regarding the "Human IL-17F Kit (HICA)" (Catalog No.: UA086043), please feel free to contact us.
This article is reviewed and published by the technical expert team of UA
Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.
Purchase recombinant protein, choose Nanjing UA-Bio
UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Youai is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.
Business license (three certificates in one) 